Status:
TERMINATED
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Dr. Jeffrey Thomas Stroke Shield Foundation
Conditions:
Subarachnoid Hemorrhage
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant again...
Eligibility Criteria
Inclusion
- diagnosis of spontaneous SAH
- impaired cerebral autoregulation on day 2-4 post SAH
Exclusion
- traumatic SAH
- other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
- pregnancy
- severe renal disease or anuria
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02216513
Start Date
September 1 2014
End Date
July 1 2015
Last Update
July 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115